1. Report Introduction 2. Cutaneous T-Cell Lymphoma(CTCL) Market Overview at a Glance 2.1. Market Share Distribution of Cutaneous T-Cell Lymphoma(CTCL) in 2017 2.2. Market Share Distribution of Cutaneous T-Cell Lymphoma(CTCL) in 2027 3. Disease Background and Overview: Cutaneous T-Cell Lymphoma(CTCL) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Cutaneous T-Cell Lymphoma(CTCL) in 7MM 4.3. Total Prevalent Patient Population of Cutaneous T-Cell Lymphoma(CTCL) in 7MM – By Countries 5. Epidemiology of Cutaneous T-Cell Lymphoma(CTCL) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.1.3. Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) * 5.1.4. Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) * 5.1.5. Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.1.6. Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.4.3. Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) * 5.4.4. Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) * 5.4.5. Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.4.6. Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.5.3. Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) * 5.5.4. Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) * 5.5.5. Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.5.6. Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.6.3. Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) * 5.6.4. Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) * 5.6.5. Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.6.6. Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.7.3. Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) * 5.7.4. Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) * 5.7.5. Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.7.6. Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.8.3. Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) * 5.8.4. Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) * 5.8.5. Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.8.6. Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.9.3. Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) * 5.9.4. Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) * 5.9.5. Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) 5.9.6. Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Cutaneous T-Cell Lymphoma(CTCL) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Cutaneous T-Cell Lymphoma(CTCL) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Cutaneous T-Cell Lymphoma(CTCL) : 7MM Market Analysis 12.1. 7MM Market Size of Cutaneous T-Cell Lymphoma(CTCL) 12.2. 7MM Percentage Share of drugs marketed for Cutaneous T-Cell Lymphoma(CTCL) 12.3. 7MM Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Products 13. Cutaneous T-Cell Lymphoma(CTCL) : Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Cutaneous T-Cell Lymphoma(CTCL) in United States 13.1.2. Percentage Share of drugs marketed for Cutaneous T-Cell Lymphoma(CTCL) in United States 13.1.3. Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Cutaneous T-Cell Lymphoma(CTCL) in Germany 13.2.1.2. Percentage Share of drugs marketed for Cutaneous T-Cell Lymphoma(CTCL) in Germany 13.2.1.3. Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Cutaneous T-Cell Lymphoma(CTCL) in France 13.2.2.2. Percentage Share of drugs marketed for Cutaneous T-Cell Lymphoma(CTCL) in France 13.2.2.3. Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Cutaneous T-Cell Lymphoma(CTCL) in Italy 13.2.3.2. Percentage Share of drugs marketed for Cutaneous T-Cell Lymphoma(CTCL) in Italy 13.2.3.3. Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Cutaneous T-Cell Lymphoma(CTCL) in Spain 13.2.4.2. Percentage Share of drugs marketed for Cutaneous T-Cell Lymphoma(CTCL) in Spain 13.2.4.3. Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Cutaneous T-Cell Lymphoma(CTCL) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Cutaneous T-Cell Lymphoma(CTCL) in United Kingdom 13.2.5.3. Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Cutaneous T-Cell Lymphoma(CTCL) in Japan 13.3.2. Percentage Share of drugs marketed for Cutaneous T-Cell Lymphoma(CTCL) in Japan 13.3.3. Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight *Indication Specific

Table 1: Total Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in 7MM Table 2: Total Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in United States (2016-2027) Table 4: Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) in United States (2016-2027) Table 5: Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) in United States (2016-2027) Table 6: Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) in United States (2016-2027) Table 7: Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) in United States (2016-2027) Table 8: Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Germany (2016-2027) Table 9: Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) in Germany (2016-2027) Table 10: Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Germany (2016-2027) Table 11: Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Germany (2016-2027) Table 12: Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Germany (2016-2027) Table 13: Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in France (2016-2027) Table 14: Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) in France (2016-2027) Table 15: Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) in France (2016-2027) Table 16: Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) in France (2016-2027) Table 17: Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) in France (2016-2027) Table 18: Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Italy (2016-2027) Table 19: Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) in Italy (2016-2027) Table 20: Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Italy (2016-2027) Table 21: Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Italy (2016-2027) Table 22: Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Italy (2016-2027) Table 23: Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Spain (2016-2027) Table 24: Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) in Spain (2016-2027) Table 25: Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Spain (2016-2027) Table 26: Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Spain (2016-2027) Table 27: Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Spain (2016-2027) Table 28: Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in UK (2016-2027) Table 29: Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) in UK (2016-2027) Table 30: Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) in UK (2016-2027) Table 31: Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) in UK (2016-2027) Table 32: Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) in UK (2016-2027) Table 33: Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Japan (2016-2027) Table 34: Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) in Japan (2016-2027) Table 35: Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Japan (2016-2027) Table 36: Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Japan (2016-2027) Table 37: Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Japan (2016-2027) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Cutaneous T-Cell Lymphoma(CTCL) in USD MM (2016-2027) Table 42:7MM- Market Share Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Table 43:7MM- Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Table 44: United States-Market Size of Cutaneous T-Cell Lymphoma(CTCL) in USD MM (2016-2027) Table 45: United States-Market Share Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Table 46: United States-Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Table 47: Germany-Market Size of Cutaneous T-Cell Lymphoma(CTCL) in USD MM (2016-2027) Table 48: Germany-Market Share Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Table 49: Germany-Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Table 50: France-Market Size of Cutaneous T-Cell Lymphoma(CTCL) in USD MM (2016-2027) Table 51: France-Market Share Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Table 52: France-Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Table 53: Italy-Market Size of Cutaneous T-Cell Lymphoma(CTCL) in USD MM (2016-2027) Table 54: Italy-Market Share Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Table 55: Italy-Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Table 56: Spain-Market Size of Cutaneous T-Cell Lymphoma(CTCL) in USD MM (2016-2027) Table 57: Spain-Market Share Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Table 58: Spain-Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Table 59:UK-Market Size of Cutaneous T-Cell Lymphoma(CTCL) in USD MM (2016-2027) Table 60:UK-Market Share Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Table 61:UK-Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Table 62: Japan-Market Size of Cutaneous T-Cell Lymphoma(CTCL) in USD MM (2016-2027) Table 63: Japan-Market Share Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Table 64: Japan-Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Figure 1: Total Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in 7MM Figure 2: Total Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in United States (2016-2027) Figure 4: Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) in United States (2016-2027) Figure 5: Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) in United States (2016-2027) Figure 6: Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) in United States (2016-2027) Figure 7: Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) in United States (2016-2027) Figure 8: Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Germany (2016-2027) Figure 9: Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) in Germany (2016-2027) Figure 10: Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Germany (2016-2027) Figure 11: Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Germany (2016-2027) Figure 12: Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Germany (2016-2027) Figure 13: Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in France (2016-2027) Figure 14: Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) in France (2016-2027) Figure 15: Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) in France (2016-2027) Figure 16: Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) in France (2016-2027) Figure 17: Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) in France (2016-2027) Figure 18: Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Italy (2016-2027) Figure 19: Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) in Italy (2016-2027) Figure 20: Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Italy (2016-2027) Figure 21: Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Italy (2016-2027) Figure 22: Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Italy (2016-2027) Figure 23: Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Spain (2016-2027) Figure 24: Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) in Spain (2016-2027) Figure 25: Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Spain (2016-2027) Figure 26: Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Spain (2016-2027) Figure 27: Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Spain (2016-2027) Figure 28: Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in UK (2016-2027) Figure 29: Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) in UK (2016-2027) Figure 30: Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) in UK (2016-2027) Figure 31: Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) in UK (2016-2027) Figure 32: Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) in UK (2016-2027) Figure 33: Prevalent/Incident Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Japan (2016-2027) Figure 34: Sub-Type Specific cases of the Cutaneous T-Cell Lymphoma(CTCL) in Japan (2016-2027) Figure 35: Sex- Specific Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Japan (2016-2027) Figure 36: Diagnosed Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Japan (2016-2027) Figure 37: Treatable Cases of the Cutaneous T-Cell Lymphoma(CTCL) in Japan (2016-2027) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Cutaneous T-Cell Lymphoma(CTCL) in USD MM (2016-2027) Figure 42:7MM- Market Share Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Figure 43:7MM- Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Figure 44: United States-Market Size of Cutaneous T-Cell Lymphoma(CTCL) in USD MM (2016-2027) Figure 45: United States-Market Share Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Figure 46: United States-Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Figure 47: Germany-Market Size of Cutaneous T-Cell Lymphoma(CTCL) in USD MM (2016-2027) Figure 48: Germany-Market Share Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Figure 49: Germany-Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Figure 50: France-Market Size of Cutaneous T-Cell Lymphoma(CTCL) in USD MM (2016-2027) Figure 51: France-Market Share Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Figure 52: France-Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Figure 53: Italy-Market Size of Cutaneous T-Cell Lymphoma(CTCL) in USD MM (2016-2027) Figure 54: Italy-Market Share Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Figure 55: Italy-Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Figure 56: Spain-Market Size of Cutaneous T-Cell Lymphoma(CTCL) in USD MM (2016-2027) Figure 57: Spain-Market Share Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Figure 58: Spain-Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Figure 59:UK-Market Size of Cutaneous T-Cell Lymphoma(CTCL) in USD MM (2016-2027) Figure 60:UK-Market Share Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Figure 61:UK-Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Figure 62: Japan-Market Size of Cutaneous T-Cell Lymphoma(CTCL) in USD MM (2016-2027) Figure 63: Japan-Market Share Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027) Figure 64: Japan-Market Sales of Cutaneous T-Cell Lymphoma(CTCL) by Therapies in USD MM (2016-2027)